Preventing invasive meningococcal disease in early infancy

8Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This review considers the pathogenesis, diagnosis, and epidemiology of invasive meningococcal disease in infants, to examine and critique meningococcal disease prevention in this population through vaccination. High rates of meningococcal disease and poor outcomes, particularly for very young infants, highlight the importance of meningococcal vaccination in early infancy. Although effective and safe meningococcal vaccines are available for use from 6 weeks of age, they are not recommended globally. Emerging real-world data from the increased incorporation of these vaccines within immunization programs inform recommendations regarding effectiveness, appropriate vaccination schedule, possible long-term safety effects, and persistence of antibody responses. Importantly, to protect infants from IMD, national vaccination recommendations should be consistent with available data regarding vaccine safety, effectiveness, and disease risk.

Cite

CITATION STYLE

APA

Presa, J., Serra, L., Weil-Olivier, C., & York, L. (2022). Preventing invasive meningococcal disease in early infancy. Human Vaccines and Immunotherapeutics. Taylor and Francis Ltd. https://doi.org/10.1080/21645515.2021.1979846

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free